Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6002)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 24, 2020 (publication date) through Apr 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wilde L, Ramanathan S, Kasner M. B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia. World J Clin Oncol 2020; 11(8): 528-540 [PMID: 32879842 DOI: 10.5306/wjco.v11.i8.528] |
|---|---|
| URL: | https://www.wjgnet.com/1948-0210/full/v11/i8/528.htm |
| Number | Citing Articles |
| 1 |
Juan Tong, Na Zhao, Xing Hu, Wen Yao, Yaxin Cheng, Li Zhou, Huilan Liu, Liangquan Geng, Zimin Sun, Changcheng Zheng. Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting. Cancer Management and Research 2021; : 5613 doi: 10.2147/CMAR.S316561
|
| 2 |
Romeo G. Mihăilă. Venetoclax in Acute Myeloid Leukemia. Recent Patents on Anti-Cancer Drug Discovery 2023; 18(1): 11 doi: 10.2174/1574892817666220429105338
|
| 3 |
Abhishek Maiti, Bing Z. Carter, Michael Andreeff, Marina Y. Konopleva. SOHO State of the Art Updates and Next Questions | Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. Clinical Lymphoma Myeloma and Leukemia 2022; 22(9): 652 doi: 10.1016/j.clml.2022.04.001
|
| 4 |
Erin M Kropp, Qing Li. Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia. Experimental Hematology 2022; 111: 13 doi: 10.1016/j.exphem.2022.04.001
|
| 5 |
Linzhang Li, Chengwu Han, Xueying Yu, Jun Shen, Yongtong Cao, Enas Abdulhay. Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis. Journal of Healthcare Engineering 2022; 2022: 1 doi: 10.1155/2022/2842066
|